Medexus Pharmaceuticals Inc. (MEDXF)
| Market Cap | 48.37M |
| Revenue (ttm) | 104.76M |
| Net Income (ttm) | 2.30M |
| Shares Out | n/a |
| EPS (ttm) | 0.09 |
| PE Ratio | 21.08 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 99 |
| Open | 1.880 |
| Previous Close | 1.893 |
| Day's Range | 1.880 - 1.880 |
| 52-Week Range | 1.080 - 2.350 |
| Beta | 1.96 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 6, 2025 |
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process ...
Medexus Pharmaceuticals Inc. (MEDXF) Q2 2025 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q2 2025 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Ken d'Entremont - CEO Brendon Bu...
Medexus Announces Strong Fiscal Q2 2025 Results
Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 million Management to host conference call at 8:00 AM Eastern time o...
Medexus Schedules Second Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 29, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, Novem...
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareho...
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization ri...
Medexus Announces Strong Fiscal Q1 2025 Results
Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 million Management to host conference call at 8:00 AM Eastern time o...
Medexus Schedules First Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August...
Medexus Pharmaceuticals Inc. (MEDXF) Q4 2024 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q4 2024 Earnings Conference Call June 26, 2024 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Kenneth d'Entremont - CEO Marcel Ko...
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024
FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25,...
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June ...
FDA Accepts for Review Treosulfan NDA Resubmission
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's comm...
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Met...
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the...
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Il...
Medexus Pharmaceuticals Inc. (MEDXF) Q3 2024 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (MEDXF) Q3 2024 Earnings Call Transcript
Medexus Announces Fiscal Q3 2024 Results
Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024...
Medexus Schedules Third Fiscal Quarter 2024 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Feb...
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
Topical terbinafine has been widely used in other markets to treat fungal nail infections If and when approved, the product will enter the topical fungicides market that is estimated to be C$88 millio...
Medexus Pharmaceuticals, Inc. (MEDXF) Q2 2024 Earnings Call Transcript
Medexus Pharmaceuticals, Inc. (OTCQX:MEDXF) Q2 2024 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Magda Gardner - IR Representative, Adelaide Capital Kenneth d'Entremont - ...
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performance Management to host conference call at 8:00 AM Eastern time on...
Medexus Schedules Second Fiscal Quarter 2024 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Nov...
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that, in connection with its recently completed b...
Medexus Fully Repays Convertible Debentures In Cash At Maturity
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 16, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has made in cash the final maturity date payment of C$51.1 million (or a...
Medexus Announces Closing of C$10 Million Bought-Deal Public Offering
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 6, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the closing of its bought-deal public offering of ...